Literature DB >> 17031316

Viral load and CD4 count dynamics after HIV-1 seroconversion in homosexual and bisexual men in Rio de Janeiro, Brazil.

Gaston Djomand1, Ann Duerr, José Cláudio Faulhaber, Claudio J Struchiner, A Guilherme Pacheco, Paulo F Barroso, M Fatima Melo, Mauro Schechter.   

Abstract

PURPOSE: Reliable predictors of HIV disease progression are scarce in developing countries, where most HIV infections occur. We describe early virologic and immunologic events among men who have sex with men in Rio de Janeiro, Brazil.
METHODS: Seroconverters from 2 high-risk cohorts were followed for up to 36 months with periodic laboratory evaluations, plasma viral load, and CD4 count assessments. Viral load and CD4 count mean trajectories were computed. For the modeled viral loads, mean and median values were 24,480 (4.36 log10) and 19,720 (4.29 log10) copies/mL (range 14,880-58,090), respectively. Median CD4 count was 373 cells/microL (range 260-508). Overall variation on viral loads ranged from 4.3 to 5.2 log10 copies/mL with a visible increase in the viral load starting at approximately 600 days (n = 12) after estimated time of seroconversion. The initial period of HIV infection was characterized by an increase in CD4 count (n = 29) followed by a steep decline starting at approximately 200 days (508 cells, 95% CI: 425 to 569). A gradual decrease was observed in the median CD4 count thereafter, reaching 281 (95% CI: 100 to 466) at 1000 days after the estimated date of seroconversion.
CONCLUSIONS: Although viral load dynamics resembled those observed in developed countries, CD4 counts seem to decline at a faster rate than in the Multicenter AIDS Cohort Study (MACS) cohort. Clinical and survival data are needed to assess the impact of interventions, such as antiretroviral therapy, on the clinical course of HIV infection in Brazil.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17031316     DOI: 10.1097/01.qai.0000243117.21788.90

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  6 in total

1.  HIV & Hepatitis in the Americas 28-30 April 2016, Mexico City, Mexico.

Authors: 
Journal:  J Int AIDS Soc       Date:  2016-04-28       Impact factor: 5.396

2.  CD4 dynamics over a 15 year-period among HIV controllers enrolled in the ANRS French observatory.

Authors:  Faroudy Boufassa; Asier Saez-Cirion; Jérome Lechenadec; David Zucman; Véronique Avettand-Fenoel; Alain Venet; Christine Rouzioux; Jean-François Delfraissy; Olivier Lambotte; Laurence Meyer
Journal:  PLoS One       Date:  2011-04-21       Impact factor: 3.240

3.  Acute retroviral syndrome and high baseline viral load are predictors of rapid HIV progression among untreated Argentinean seroconverters.

Authors:  M Eugenia Socías; Omar Sued; Natalia Laufer; María E Lázaro; Horacio Mingrone; Daniel Pryluka; Carlos Remondegui; María I Figueroa; Carina Cesar; Ana Gun; Gabriela Turk; María B Bouzas; Ravi Kavasery; Alejandro Krolewiecki; Héctor Pérez; Horacio Salomón; Pedro Cahn
Journal:  J Int AIDS Soc       Date:  2011-08-10       Impact factor: 5.396

4.  Disease progression by infecting HIV-1 subtype in a seroconverter cohort in sub-Saharan Africa.

Authors:  Pauli N Amornkul; Etienne Karita; Anatoli Kamali; Wasima N Rida; Eduard J Sanders; Shabir Lakhi; Matt A Price; William Kilembe; Emmanuel Cormier; Omu Anzala; Mary H Latka; Linda-Gail Bekker; Susan A Allen; Jill Gilmour; Patricia E Fast
Journal:  AIDS       Date:  2013-11-13       Impact factor: 4.177

5.  Modeling the Slow CD4+ T Cell Decline in HIV-Infected Individuals.

Authors:  Sunpeng Wang; Patricia Hottz; Mauro Schechter; Libin Rong
Journal:  PLoS Comput Biol       Date:  2015-12-28       Impact factor: 4.475

6.  Late presentation to HIV testing is overestimated when based on the consensus definition.

Authors:  A Sasse; E Florence; A Pharris; S De Wit; P Lacor; D Van Beckhoven; J Deblonde; M-L Delforge; K Fransen; J-C Goffard; J-C Legrand; M Moutschen; D Piérard; J Ruelle; D Vaira; B Vandercam; M Van Ranst; E Van Wijngaerden; L Vandekerckhove; C Verhofstede
Journal:  HIV Med       Date:  2015-07-28       Impact factor: 3.180

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.